May 9, 2019—Beckman Coulter announced that its DxA 5000 total laboratory automation solution has achieved the CE mark and China Food and Drug Administration approval. The DxA 5000 aims to deliver rapid and consistent turnaround time, provide a new level of comprehensive preanalytical sample quality detection, and reduce the number of manual processing steps.
The system is designed with a focus on sample quality assessment, screening each sample at many points to help laboratories substantially reduce the risk of errors. In three seconds, the system detects patient tube parameters such as volume, sample identification, tube type, cap color, orders pending, and tube weight. The system checks for sample volume at three points—pre-centrifugation, post-centrifugation, and prior to sample storage—to ensure sufficient volume is available for the tests ordered. It continuously calculates the most expeditious route for every patient sample, both stat and routine, by understanding the tests requested, sample volume available, and real-time analyzer capacity and status.
“Based on research and work performed with our laboratory partners, sample processing steps are shown to make up approximately 70 percent of a laboratory’s labor hours,” John Blackwood, senior vice president of products and services, Beckman Coulter, said in a press release. “The DxA 5000 significantly reduces the number of manual steps in sample processing to as few as one. From sample accessioning and quality assessment to add-on test management and sample disposal, the DxA 5000 enables laboratory professionals to deliver high-quality results and improve efficiency, empowering them to focus their efforts and skills on managing patient sample exceptions.”
Beckman Coulter reports it has received purchase orders for more than 20 DxA 5000 systems in countries where regulatory clearance has been achieved. A 510(k) submission is pending FDA clearance.